Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
08/2012
08/28/2012US8252332 Gastric retained gabapentin dosage form
08/28/2012US8252283 Method for treating vascular disorders
08/28/2012CA2825216A1 Method for enhancing efficacy and selectivity of cancer cell killing by dna damaging agents
08/28/2012CA2656910C Anti-cancer therapy comprising an h2-blocker, at least one antiinflammatory agent and a cytotoxic agent
08/28/2012CA2519679C Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
08/28/2012CA2479414C Inhibition of the .beta.3 subunit of l-type ca2+ channels
08/28/2012CA2476939C Pharmaceutical combinations of cox-2 inhibitors and opiates
08/28/2012CA2454073C Mutations in ion channels
08/28/2012CA2412531C Antimicrobial peptides and methods of use thereof
08/28/2012CA2387805C Nucleic acids encoding endotheliases, endotheliases and uses thereof
08/23/2012WO2012112847A1 mTOR/JAK INHIBITOR COMBINATION THERAPY
08/23/2012WO2012112531A1 Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases
08/23/2012WO2012112527A1 Omega 3 formulations comprising epa, dha and dpa for treatment of risk factors for cardiovascular disease
08/23/2012WO2012112520A1 A formulations comprising omega 3 fatty acids and an anti obesity agent for the reduction of body weight in cardiovascular disease patients (cvd) and diabetics
08/23/2012WO2012112517A1 Omega 3 fatty acid diagniostic assay for the dietary management of patients with cardiovascular disease (cvd)
08/23/2012WO2012112511A1 Cholesterol absorption inhibitor (azetidinone) and omega 3 fatty acids (epa, dha, dpa) for the reduction of cholesterol and for the reduction of cardiovascular events
08/23/2012WO2012111852A1 Therapeutic agent for vertebral body fracture and method for evaluating same
08/23/2012WO2012111790A1 Potentiator of antitumor activity of chemotherapeutic agent
08/23/2012WO2012110953A1 Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases
08/23/2012US20120214880 Cancer screening by detection of ultrastructural and molecular markers
08/23/2012US20120214866 Treatment with cytokines
08/23/2012US20120214819 Use of N--4-(3-pyridyl)-2-pyridine-amine for the Treatment of Pulmonary Hypertension
08/23/2012US20120214774 Treatment of solid tumors with rapamycin derivatives
08/23/2012US20120214772 Compositions for treatment of inflammatory diseases
08/23/2012US20120214763 Memory fixation accelerator
08/23/2012US20120214738 Therapeutic agent and therapeutic method for periodontal diseases and pulpal diseases
08/23/2012US20120213831 Microspheres for active embolization
08/23/2012US20120213829 Dry powder aerosols of nanoparticulate drugs
08/23/2012US20120213824 Use of pufas for treating skin inflammation
08/23/2012US20120213822 Chemo-immunotherapy method
08/23/2012US20120213804 Calicheamicin derivative-carrier conjugates
08/23/2012US20120213778 Method of detecting and treating tuberous sclerosis complex associated disorders
08/23/2012US20120213777 Vascular endothelial growth factor 2
08/23/2012US20120213731 Methods and compositions for treating autoimmune diseases
08/23/2012US20120213730 Alteration of cell membrane for new functions
08/23/2012CA2827673A1 Mtor/jak inhibitor combination therapy
08/23/2012CA2827585A1 Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases
08/23/2012CA2827579A1 Omega 3 formulations comprising epa, dha and dpa for treatment of risk factors for cardiovascular disease
08/23/2012CA2827577A1 A formulations comprising omega 3 fatty acids and an anti obesity agent for the reduction of body weight in cardiovascular disease patients (cvd) and diabetics
08/23/2012CA2827561A1 Omega 3 fatty acid diagniostic assay for the dietary management of patients with cardiovascular disease (cvd)
08/23/2012CA2827555A1 Cholesterol absorption inhibitor (azetidinone) and omega 3 fatty acids (epa, dha, dpa) for the reduction of cholesterol and for the reduction of cardiovascular events
08/22/2012EP2489370A1 Use of a synergistic compound as a therapeutic agent or disinfectant
08/22/2012EP2489369A1 A method of treating Hepatitis C patients
08/22/2012EP2489357A1 Novel Triclosan Salts
08/22/2012EP2489355A1 Wound-healing composition
08/22/2012EP2489348A1 Pharmaceutical composition containing medicament-containing fine particles and method for producing same
08/22/2012EP2488642A1 Compositions and methods for the treatment of drug-induced hand-foot syndrome
08/22/2012EP2488205A1 Recombinant human cc10 protein for treatment of influenza
08/22/2012EP2488192A1 Combinations of a specific hcv ns5a inhibitor and an hcv ns3 protease inhibitor
08/22/2012EP2488183A2 Composition for inhibiting tgf- comprising imidazopurine derivatives
08/22/2012EP2488179A2 Nrf2 inhibitors and use thereof
08/22/2012EP2488170A1 Compositions comprising tramadol and celecoxib in the treatment of pain
08/22/2012EP2488026A1 The use of a par-1 antagonist in combination with a p2y12adp receptor antagonist for inhibition of thrombosis
08/22/2012EP2488020A1 3-substituted compounds for reducing uric acid
08/22/2012EP1768679B1 Modulation of gsk-3beta and method of treating proliferative disorders
08/22/2012EP1732524B1 Methods and compositions for treatment of ion imbalances
08/22/2012EP1646425B1 Parasiticidal composition
08/22/2012EP1401829B1 Novel heterocyclic antibacterial compounds
08/22/2012CN1935146B Anti-cytochrome oxidase P450 inhibitor medicinal composition and its use
08/22/2012CN1441676B Method of treatment using ligand-immunogen conjugates
08/22/2012CN102647985A Methods of using c-Met modulators
08/22/2012CN102643333A Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
08/22/2012CN102643256A Arylglucoside compound and preparation method and application thereof
08/22/2012CN102643233A Analogs of benzoquinone-containing ansamycins for the treatment of cancer
08/22/2012CN102641503A Inhibitors of angiopoietin-like 4 protein, combinations, and their use
08/22/2012CN102641502A Novel use of aromatase inhibitors
08/22/2012CN102641501A Application of NALP3-ASC inflammation complex and activator inhibitor thereof in terms of preparation of medicines for treating prion diseases
08/21/2012US8247424 Water soluble groups on ring A; antitumor antibiotics; 1-Desoxy-5-C-[(8R)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3-yl]pentitol; topoisomerase inhibitors; cyclodextrin inclusions; stereoisomers
08/21/2012US8247231 Methods and compositions for producing antigenic responses
08/21/2012US8246989 Dosage forms of bisphosphonates
08/21/2012US8246987 Controlled release composition and method of producing the same
08/21/2012US8246944 Immunotherapeutic agent for the combined treatment of tuberculosis in association with other drugs
08/21/2012US8246934 Respiratory dispersion for metered dose inhalers comprising perforated microstructures
08/21/2012CA2689429C Bicycloaniline derivatives
08/21/2012CA2633413C Antibodies against tumor-associated antigenic target (tat) polypeptides
08/21/2012CA2562190C Novel antiviral pharmaceutical composition
08/21/2012CA2543793C Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pain
08/21/2012CA2495830C The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
08/21/2012CA2472920C Methods of reducing angiogenesis
08/21/2012CA2469076C Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses
08/21/2012CA2459794C Vascular occlusion solid-phase agent with immobilised platelet binding agent
08/21/2012CA2434388C Activated charcoal based composition and method for reducing hangover symptoms associated with the consumption of alcohol containing beverages
08/21/2012CA2408032C Preparation for the prevention and/or treatment of vascular disorders
08/21/2012CA2390129C Slimming composition containing a substance inducing il-6 production
08/21/2012CA2371723C Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
08/21/2012CA2312975C Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
08/21/2012CA2233924C Novel stable liquid paracetamol compositions, and method for preparing same
08/21/2012CA2209021C Bacterial and synthetic polysaccharides for the enhancement of general immunity
08/16/2012WO2012109642A1 Aqueous extraction methods for high lipid microorganisms
08/16/2012WO2012108548A1 TRANSFORMANT HAVING Gm1 GENE, GPCR GENE, AND CRMP2 GENE INTRODUCED THEREIN
08/16/2012WO2012108379A1 Therapeutic agent for diastolic congestive heart failure
08/16/2012WO2012107769A1 Treatment of allergic disorders
08/16/2012WO2012107416A2 Improved immunotherapy
08/16/2012WO2012107364A1 Novel composition for the treatment of cystic fibrosis
08/16/2012WO2012069150A3 Cytoprotectant agents for the prevention of drug-associated side-effects
08/16/2012US20120210465 Production of Polyunsaturated Fatty Acids, Novel Biosynthesis Genes, And Novel Plant Expression Constructs
08/16/2012US20120209012 Compounds, compositions and methods
08/16/2012US20120208900 Methods of predicting the need for surgery in crohn's disease
08/16/2012US20120208774 Method for inhibiting "melanoma inhibitory activity" mia
08/16/2012US20120207855 Cephalotaxine alkaloid compositions and uses thereof
1 ... 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 ... 1151